AnGes (4563) AI Stock Analysis

• Market Cap: ¥32.04B
• Dividend Yield: N/A
• Average Volume (3M): 14.35M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: 58.24%
• EPS Growth: -234.81%
• Country: JP
• Employees: 55
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -8.08
• Shares Outstanding: 386,077,550
• 10 Day Avg. Volume: 7,318,560
• 30 Day Avg. Volume: 14,350,710
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥96.97
• Price Target Upside: 16.84% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 44 Neutral
• Price Target: ¥83.00 ▲(0.00% Upside)

AnGes's overall stock score is primarily impacted by its poor financial performance, characterized by significant losses and cash flow challenges. While technical analysis shows some positive momentum, the negative valuation metrics further weigh down the score. The absence of earnings call data and corporate events leaves the financial and technical aspects as the primary determinants of the score.

AnGes Business Overview & Revenue Model

Company Description

AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of critical limb ischemia, a serious impairment of blood circulation in the leg. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and disc degeneration; medical devices for the prevention of vascular restenosis; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University. AnGes, Inc. has alliances with BioMarin Pharmaceutical Inc. to market Naglazyme, a drug for the treatment of mucopolysaccharidosis VI in Japan; and Mitsubishi Tanabe Pharma Corporation for marketing HGF Plasmid for the treatment of peripheral arterial disease in the United States and Japan. It also has alliances with SHIONOGI & CO., LTD. for the marketing of drugs for external use containing NF-kB decoy oligonucleotide for skin diseases; Vical, Inc. for the development and marketing of Allovectin for cancer treatment; and Osaka University to develop a coronavirus vaccine. In addition, the company has a collaboration agreement with Brickell Biotech, Inc. to develop investigational plasmid DNA vaccine intended to prevent coronavirus in the United States, South America, and other markets. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.

How the Company Makes Money

AnGes makes money primarily through the development and commercialization of its gene therapy products. The company's revenue streams are driven by product sales, licensing agreements, and collaborative partnerships with pharmaceutical companies and research institutions. AnGes engages in strategic partnerships to co-develop and out-license its innovative therapies, which allows it to generate upfront payments, milestone payments, and royalties. Additionally, the company may also receive funding and grants from governmental and non-governmental organizations to support its research and development efforts.

AnGes Financial Statement Overview

Summary

AnGes faces significant financial challenges with deeply negative EBIT and Net Income margins, persistent negative free cash flow, and reliance on external financing. Despite a low debt-to-equity ratio, the company's financial health is concerning due to continuous losses and cash flow issues.

Income Statement

AnGes has faced significant challenges in maintaining profitability. The company's EBIT and Net Income margins are deeply negative, indicating considerable losses. While revenue has grown from previous periods, the growth is overshadowed by substantial operating losses. This points to potential structural or strategic challenges in its operations.

Balance Sheet

The balance sheet reflects a moderate financial structure with some areas of concern. The debt-to-equity ratio is low, which is a positive sign of limited leverage. However, the consistent decline in stockholders' equity over recent years and negative net income impact return on equity. Despite a negative net debt position, indicating more cash than debt, persistent losses raise concerns about long-term sustainability.

Cash Flow

Cash flow analysis reveals ongoing cash constraints, with persistent negative free cash flow. The operating cash flow is also negative, further emphasizing cash management challenges. The company has relied on financing activities to support cash flow needs, indicating a dependency on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	699.25M	643.00M	152.99M	67.06M	64.15M	40.00M
Gross Profit	232.21M	247.00M	19.45M	-2.92B	7.43M	16.98M
EBITDA	-5.40B	-5.74B	-8.86B	-13.41B	-13.21B	-4.19B
Net Income	-27.55B	-28.13B	-7.44B	-14.71B	-13.68B	-4.21B
Balance Sheet
Total Assets	5.68B	4.67B	28.89B	38.82B	45.46B	38.35B
Cash, Cash Equivalents and Short-Term Investments	2.68B	1.71B	4.16B	11.04B	17.90B	11.54B
Total Debt	219.96M	272.45M	362.68M	1.16B	0.00	0.00
Total Liabilities	2.46B	2.51B	2.79B	8.40B	6.82B	5.67B
Stockholders Equity	3.22B	2.16B	26.10B	30.43B	38.63B	32.68B
Cash Flow
Free Cash Flow	0.00	-6.69B	-8.84B	-11.23B	-11.46B	-3.04B
Operating Cash Flow	0.00	-6.61B	-8.74B	-11.21B	-11.38B	-2.96B
Investing Cash Flow	0.00	-130.80M	-356.65M	-97.14M	-154.87M	-6.96B
Financing Cash Flow	0.00	4.20B	2.04B	3.57B	17.38B	11.40B

AnGes Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 83.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4563, the sentiment is Neutral. The current price of 83 is below the 20-day moving average (MA) of 93.85, above the 50-day MA of 81.70, and above the 200-day MA of 66.10, indicating a neutral trend. The MACD of -0.76 indicates Positive momentum. The RSI at 45.50 is Neutral, neither overbought nor oversold. The STOCH value of 31.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4563.

AnGes Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7774	58 Neutral	¥20.71B	-72.28	―	―	6.33%	-250.29%
7776	51 Neutral	¥15.77B	-15.22	-39.75%	―	-22.81%	2.69%
4599	47 Neutral	¥18.83B	-9.73	―	―	―	5.59%
4593	46 Neutral	¥64.40B	-9.12	-476.97%	―	-78.54%	10.23%
4563	44 Neutral	¥32.04B	―	-207.91%	―	58.24%	-234.81%
4575	32 Underperform	¥23.16B	-19.20	―	―	―	9.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%